Day: May 9, 2024

Product Sales up a robust 14% over prior year, and a significant 22% sequentially We believe the STAR-T data presented at AATS support a favorable benefit-to-risk profile of DrugSorb-ATR in coronary artery bypass graft (CABG) patients On track for U.S. Food and Drug Administration (FDA) De Novo and Health Canada submissions for DrugSorb®-ATR in Q3 2024PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended March 31, 2024. The Company reported a robust 14% increase in product sales year over year and a sequential quarterly increase of 22%. Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, “We are pleased to announce a...

ROCHESTER, N.Y., May 09, 2024 (GLOBE NEWSWIRE) — Eastman Kodak Company (NYSE: KODK) today reported financial results for the first quarter 2024. First-quarter 2024 highlights include:Consolidated revenues of $249 million, compared with $278 million for Q1 2023, a decrease of $29 million or 10 percent Gross profit of $49 million, compared with $50 million for Q1 2023, a decrease of $1 million or 2 percent Gross profit percentage of 20 percent, compared with 18 percent for Q1 2023, an increase of 2 percentage points GAAP net income of $32 million, compared with net income of $33 million for Q1 2023, a decrease of $1 million or 3 percent Operational EBITDA of $4 million, compared with $9 million for Q1 2023, a decrease of $5 million or 56 percent A quarter-end cash balance of $262 million, compared with $255 million on December...

Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab, our PD-1 agonist; reiterating top-line data anticipated by mid 2025 and H1 2026, respectively IND submissions for ANB033 (anti-CD122 antagonist) and ANB101 (BDCA2 modulator) anticipated Q2 2024 and H2 2024, respectively Announced positive top-line GEMINI-2 Phase 3 trial results of imsidolimab, our IL-36R mAb, in generalized pustular psoriasis Announced a $50 million capped non-recourse royalty monetization from amended agreement with Sagard in exchange for additional Jemperli royaltiesSAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE)...

– Q2 Sales increase 9% to $249 Million – Q2 GAAP EPS increases 30% to $0.90 – Q2 Adjusted EPS increases 24% to $0.94 – St. Louis, May 09, 2024 (GLOBE NEWSWIRE) — ESCO Technologies Inc. (NYSE: ESE) (ESCO, or the Company) today reported its operating results for the second quarter ended March 31, 2024 (Q2 2024). Operating HighlightsQ2 2024 Sales increased $20.0 million (9 percent) to $249.1 million compared to $229.1 million in Q2 2023. Q2 organic sales increased $17.8 million (8 percent) and the MPE acquisition contributed $2.2 million (1 percent) of revenue in the quarter.    Q2 2024 GAAP EPS increased 30 percent to $0.90 per share compared to $0.69 per share in Q2 2023. Q2 2024 Adjusted EPS increased 24 percent to $0.94 per share compared to $0.76 per share in Q2 2023. Q2 2024 Entered Orders decreased...

FARGO, N.D., May 09, 2024 (GLOBE NEWSWIRE) — NI Holdings, Inc. (NASDAQ: NODK) announced today results for the quarter ended March 31, 2024. Summary of First Quarter 2024 Results(All comparisons vs. the first quarter of 2023, unless noted otherwise)Direct written premiums of $102.7 million, up 13.4%, driven by increases in Non-Standard Auto (23.2%), Home and Farm (13.1%) and Private Passenger Auto (7.9%). Net earned premiums of $85.6 million, up 10.2%. Combined ratio of 97.2% versus 112.2%, driven by the earned impact of prior period rate increases across all segments (excluding Crop) and lower weather-related losses in Private Passenger Auto and Commercial, partially offset by unfavorable development in Non-Standard Auto. Net investment gain of $1.8 million and net investment income of $3.6 million, driven by improved equity...

PITTSBURGH, May 09, 2024 (GLOBE NEWSWIRE) — Montauk Renewables, Inc. (“Montauk” or “the Company”) (NASDAQ: MNTK), a renewable energy company specializing in the management, recovery, and conversion of biogas into renewable natural gas (“RNG”), today announced financial results for the first quarter ended March 31, 2024. First Quarter Financial Highlights:Revenues of $38.8 million, increased 102.5% compared to the first quarter of 2023Net Income of $1.9 million, increased 148.8% compared to the first quarter of 2023Non-GAAP Adjusted EBITDA of $9.5 million, increased 212.7% compared to the first quarter of 2023RNG production of 1.4 million MMBtu, increased 4.4% compared to the first quarter of 2023RINs Sold of 7.9 million, increase of 167.5% compared to the first quarter of 2023Our profitability is highly dependent...

Strong performance versus guidance Total operating expenses declined 15% sequentially and 25% year-over-year GAAP net loss sharply reduced by $76M year-over-year, returned to adjusted profitability Additional $150M whole loan sale agreement executed in May Raising full year 2024 Total Revenue and Adjusted EBITDA guidance SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) — Oportun Financial Corporation (Nasdaq: OPRT) (“Oportun”, or the “Company”) today reported financial results for the first quarter ended March 31, 2024. “Our first quarter results reflect an important first step in our 2024 business recovery, as we sharply reduced our prior-year GAAP operating loss by $76 million while returning to adjusted profitability,” said Raul Vazquez, CEO of Oportun. “Our cost reduction efforts continue...

First Quarter 2024:Revenue down 40% from Q1 2023 Gross profit down 40% from Q1 2023 Operating Expenses down 31% from Q1 2023 Operating Loss increased 2% from Q1 2023 Net Income of $1.2M, Net Loss attributable to common shareholders of $10.1M Adjusted EBITDA loss of $1.5MMINNETONKA, Minn., May 09, 2024 (GLOBE NEWSWIRE) — Pineapple Energy Inc. (NASDAQ: PEGY), a leading provider of sustainable solar energy and back-up power to households and small businesses, today announced financial results for the first quarter ended March 31, 2024. Pineapple CEO Kyle Udseth commented, “The first quarter of 2024 presented the toughest operating conditions we’ve faced in our time as a public company. Negative Q1 EBITDA is not uncommon in the rooftop solar industry due to seasonality and timing, but we did unfortunately break our prior streak...

Revenue of $691 million in the First Quarter, down 9% Year-over-Year Private Cloud Revenue was $268 million, down 15% Year-over-Year Public Cloud Revenue was $422 million, down 5% Year-over-Year First Quarter 2024 Cash Flow Used in Operating Activities was $(90) million which includes certain one-time fees related to the debt refinancing; Cash Flow From Operating Activities was $287 million on a Trailing-Twelve-Month BasisSAN ANTONIO, May 09, 2024 (GLOBE NEWSWIRE) — Rackspace Technology, Inc. (Nasdaq: RXT), a leading end-to-end, hybrid, multicloud, and AI solutions company, today announced results for its first quarter ended March 31, 2024. Amar Maletira, Chief Executive Officer, stated, “I’m pleased to announce that first quarter 2024 results exceeded the high-end of guidance for revenue, operating profit, and EPS. We continue...